Literature DB >> 2140549

Controversies in the use of combination therapy in the older patient.

J A Schoenberger1.   

Abstract

Monotherapy of hypertension should be the goal of treatment. Even in the elderly hypertensive patient there is a good response to monotherapy with angiotensin-converting enzyme inhibitors as well as to diuretics and calcium channel blockers, despite the low plasma renin activity seen in the elderly. Adverse effects on metabolism and quality of life should be avoided in elderly patients as well as in younger hypertensive patients. Combinations of 2 drugs will not necessarily eliminate these undesirable effects, but drug combinations will be required in half of the hypertensive population. It is reasonable, when a second drug is added, to use one with a different mode of action. The role of diuretics, which have been the mainstay of antihypertensive therapy for a long time, may ultimately become that of a second drug in combination treatment.

Entities:  

Mesh:

Year:  1990        PMID: 2140549     DOI: 10.2165/00003495-199000392-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

Review 2.  First-line and combination treatment for hypertension.

Authors:  J L Reid
Journal:  Am J Med       Date:  1989-04-17       Impact factor: 4.965

Review 3.  Emerging benefits of angiotensin converting enzyme inhibitors versus other antihypertensive agents.

Authors:  J A Schoenberger
Journal:  Am J Med       Date:  1988-04-15       Impact factor: 4.965

Review 4.  University of California, Davis, conference: Mild hypertension.

Authors:  M P Sambhi; A V Chobanian; S Julius; R H Noth; N O Borhani; H M Perry
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

5.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.